.Merck trumps earnings expectations, brings up sales overview on strong requirement for leading medicines like Keytruda CNBCMerck & Co. (MRK US) Defeats Revenue Projections as Keytruda Purchases Surge BloombergMerck Sell: Pharma Titan Posts Tough Results, However Outlook Falls Short Capitalist's Service DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck beats earnings as well as purchases desires amidst Keytruda strong point, however supplies blended full-year outlook MarketWatch.